We compared serum cytoketatin19-2G2 levels in breast cancer with that in healthy and benign controls respectively, explore the correlation of serum CK19-2G2 with CEA, CA153 and clinicopathological characteristics, and finally evaluate the prognostic value of serum CK19-2G2 in breast cancer patients. Here, CEACAM5 is linked to breast carcinoma.